A

AbbVie

Global biopharmaceutical company developing medicines

Principal Clinical Pathologist

Full-TimeUpdated
$141.5k - $268.5k/yr+ Long-term incentive program eligibility
Expert
PhD, MD
North Chicago, IL, USA
In PersonOn-site role; collaboration includes team members at multiple sites.
Biology & Biotech

About the job

Requirements
  • Doctor of Veterinary Medicine (DVM or equivalent) is required.
  • Board certification in Clinical Pathology (ACVP or equivalent) is required.
  • Critical thinking and problem-solving skills are required.
  • Strong interpersonal, written, and oral communication skills are required.
  • Ability to develop and execute complex strategies is required.
  • Ability to build strong relationships with peers and cross-functionally with partners outside the team is required.
  • Ability to actively participate with leadership skills in multidisciplinary scientific teams is required.
  • A strong sense of personal responsibility and integrity, and a strong commitment to quality, are required.
Responsibilities
  • Evaluate clinical pathology data sets and integrate findings into descriptive and interpretive text for pathology reports from regulatory toxicity studies intended to support development of new therapeutics.
  • Perform scientific reviews of clinical pathology reports generated by partner organizations.
  • Communicate key clinical pathology findings and correlations to scientific teams from a broad variety of backgrounds.
  • Serve as a subject matter expert to inform and optimize clinical pathology support for preclinical programs.
  • Coordinate cross-functionally with biomarker scientists, pathologists, toxicologists, and other scientists from multiple sites to explore mechanisms of toxicity.
  • Contribute to regulatory submissions and other relevant documentation.
  • Partner with medical technologists, biomarker scientists, and pathologists on site in Lake County and across multiple sites to continually optimize laboratory capabilities and support scientific development for team members.
Desired Qualifications
  • A Ph.D. in pathology or a related scientific discipline is desirable.
  • Previous experience in the pharmaceutical industry or a contract research organization is desirable.

About the company

A

AbbVie

View
Website

AbbVie is a global biopharmaceutical company that develops and sells medicines to treat serious health conditions. Its portfolio spans immunology, oncology, virology, neuroscience, and aesthetics, with products designed to modulate the immune system, target disease pathways, or support medical aesthetics. AbbVie compounds its products through a heavy emphasis on research and development, investing billions to build a steady pipeline of new therapies. Its medicines are brought to market by selling to healthcare providers, hospitals, and clinics, and in some cases directly to patients via prescriptions. The company differentiates itself through a wide, globally distributed product line, substantial R&D investment, and a commitment to sustainability and patient care, including science-based targets. AbbVie’s goal is to improve patient outcomes by delivering effective treatments for unmet medical needs while pursuing long-term, responsible growth across healthcare markets.

Company Size

10,001+

Company Stage

IPO

Headquarters

North Chicago, Illinois

Founded

1888

Get referred to AbbVie

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Apogee acquisition closed in 2026, expanding AbbVie’s immunology pipeline beyond Skyrizi and Rinvoq.
  • EU approvals for RINVOQ and EPKINLY in September 2026 broaden ex-U.S. revenue.
  • JUVMO launches in October 2026, adding a fresh neuroscience revenue line.

What critics are saying

  • Humira, Skyrizi, and Rinvoq concentration keeps AbbVie exposed if immunology growth slows in 2027.
  • Niaspan antitrust MDL and Biocell ALCL settlements carried $1.7 billion litigation accrual by June 2026.
  • Generic ubrogepant and atogepant suits threaten Ubrelvy and Qulipta exclusivity within years.

What makes AbbVie unique

  • Skyrizi and Rinvoq anchor AbbVie’s post-Humira immunology franchise across 11 EU RINVOQ indications.
  • JUVMO’s September 28, 2026 FDA approval gives AbbVie first-in-class Parkinson’s D1/D5 therapy.
  • AbbVie pairs blockbuster cash flows with Apogee, Iambic, and Valkai deal-making.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget

Growth & Insights and Company News

6 month growth

3%

1 year growth

4%

2 year growth

4%
Yahoo Finance
Oct 30th, 2026
CDs yield 1.76% while AbbVie lifts its dividend to $1.82: which suits retirees?

AbbVie raised its quarterly dividend to $1.82 from $1.73 per share on October 30, 2026, a raise no certificate of deposit (CD) can match. The national average yield on a 12-month CD was 1.76% as of October 1, 2026, and a bank cannot cut that rate during the term. Dividends carry risk, though. Companies can cut payouts, and share prices can fall. Johnson & Johnson has raised its dividend for 64 straight years, and Procter & Gamble for 70. Tax also matters. CD interest is taxed as ordinary income, while qualified dividends face rates of 0%, 15%, or 20%. That edge disappears inside a traditional individual retirement account (IRA).

PR Newswire
Oct 30th, 2026
AbbVie Q3 revenue up 10.3% to $17.4B, raises 2026 EPS guidance

AbbVie reported third-quarter net revenues of $17.404 billion, up 10.3% on a reported basis and 10.5% at constant currency. Diluted earnings per share (EPS) rose over 100% to $2.37 on a GAAP basis, while adjusted EPS was $3.82. Immunology revenues grew 16.3% to $9.165 billion, led by Skyrizi at $5.776 billion and Rinvoq at $2.706 billion. Neuroscience revenues rose 19.4% to $3.389 billion. Oncology rose 0.8% to $1.696 billion, and aesthetics fell 1.4% to $1.176 billion. The company completed its acquisition of Apogee Therapeutics and raised its 2026 adjusted EPS guidance to $13.95–$13.99, from $13.76–$13.96. It also announced a 5.2% dividend increase, starting with the payment due in February 2027.

Yahoo Finance
Oct 28th, 2026
Abbott Laboratories sees $23.9M net ETF inflow as 25 funds buy

ETFs bought a net $23.9 million of Abbott Laboratories stock on Monday, reversing a $3.3 million outflow the previous trading day. Twenty-five funds were buyers, nine sold, and 127 held steady. IHI led the buying with $14.1 million, lifting its stake by 2.22% to 6,170,459 shares. XLV added $9.5 million and DFLV $2.1 million. Over the past five sessions, ETFs were net buyers on three days and net sellers on two. Abbott has a market cap of $178.4 billion. Trailing 12-month revenue was $48.23 billion, up 8.2% year on year. The shares trade at $103.10 and are down 15.67% this year.

Yahoo Finance
Oct 24th, 2026
AbbVie wins FDA nod for at-home Skyrizi starts in Crohn's; sales boost seen after 60-90 days

AbbVie won US Food and Drug Administration (FDA) approval on October 23 for an at-home start to Skyrizi in adults with moderately to severely active Crohn's disease. Patients previously had to begin with intravenous infusions; they can now take the first doses at home with an on-body injector. By Week 12, 74% of patients new to advanced therapy reached clinical remission, against 27% on placebo. Johnson & Johnson's rival Tremfya won similar approval about 19 months earlier. Chief commercial officer Jeff Stewart said full paid access "will probably take 60 or 90 days" because insurers must approve the regimen. Sales impact should therefore come mostly after the fourth quarter. AbbVie reports third-quarter results on October 30. It guides for revenue of about $17.2 billion; Skyrizi's franchise sold $17.562 billion in 2025.

Yahoo Finance
Oct 23rd, 2026
ETFs net sell $42.1M of AbbVie as XLV leads $32.0M exit

Exchange-traded funds (ETFs) were net sellers of AbbVie shares for a second straight session, selling a net $42.1 million on October 21. Sellers moved larger sums even though more funds bought than sold: 24 ETFs added shares and 23 cut them. The Health Care Select Sector SPDR Fund led the selling with $32.0 million, followed by iShares Core S&P 500 ETF at $9.3 million and SPDR S&P 500 ETF Trust at $2.0 million. On October 20, ETFs sold a net $6.7 million, after three days of net buying. AbbVie has a market cap of $504.0 billion. Trailing 12-month revenue was $64.39 billion, up 10.3% over the past year.